ATXS NASDAQ
Astria Therapeutics, Inc.
1W: +1.5%
1M: +3.7%
3M: +73.6%
1Y: +43.1%
3Y: -11.6%
5Y: -8.3%
$12.58
Last traded 2025-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$718.1M
52W Range3.555-13.29
Volume3,057,633
Avg Volume1,065,178
Beta0.02
Dividend—
Analyst Ratings
Company Info
CEOJill C. Milne
Employees78
SectorHealthcare
IndustryBiotechnology
IPO Date2015-06-25
Websiteastriatx.com
100 High Street
Boston, MA 02110
US
Boston, MA 02110
US
617 349 1971
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Violin Jonathan | D-Return | 14,100 | $11.35 | 2026-01-23 |
| Violin Jonathan | D-Return | 8,333 | $3.00 | 2026-01-23 |
| Violin Jonathan | D-Return | 14,100 | $9.18 | 2026-01-23 |
| Violin Jonathan | D-Return | 263,321 | — | 2026-01-23 |
| Violin Jonathan | D-Return | 14,166 | $12.24 | 2026-01-23 |